Abstract
The observation that many tumors exist in a microenvironment comprised of immune cells has led to the hypothesis that the immune system may play a significant role in the suppression of tumor growth. It is now clear that immune effector cells are capable of recognizing and destroying some cancer cells. However, tumors have developed numerous mechanisms by which they avoid immune recognition and death. Cancer immunotherapy attempts to harness the power of the immune system and direct it against tumor growth, while circumventing the immune-evasion strategies utilized by tumors. Many approaches are currently being investigated, including the re-infusion of autologous immune effector cells (i.e. cytotoxic T lymphocytes and macrophages) back into hosts after ex vivo expansion and activation. The therapeutic effects of specific cytokines are also being evaluated for their impact on tumor growth. Our lab has discovered a novel thrombospondin-1 (TSP-1) binding protein, termed “angiocidin”, with potent anti-tumor and anti-angiogenic capabilities. To further investigate the anti-tumor activity of angiocidin, we examined whether angiocidin could play a role in immune system modulation. We have found that the monocytic leukemia cell line THP-1, as well as freshly isolated human peripheral blood monocytes, differentiate into macrophage-like cells when treated with angiocidin. These cells underwent dramatic morphological changes and became more phagocytic. Angiocidin-treated monocytes also activated T lymphocytes in co-culture conditions. Angiocidin-treated THP-1 cells upregulated cytokine mRNA expression and secretion via NF-κB, MAPK, and PI3-K. Based on these data, we hypothesize that angiocidins ability to elicit tumor cell death may be mediated in part by its pro-inflammatory effects on immune cells in the tumor microenvironment.
Keywords: Angiocidin, macrophages, cancer, immunotherapy, angiogenesis, cytokine, adjuvant
Current Pharmaceutical Design
Title: The Immunomodulatory Role of Angiocidin, a Novel Angiogenesis Inhibitor
Volume: 15 Issue: 17
Author(s): A. Gaurnier-Hausser and G. P. Tuszynski
Affiliation:
Keywords: Angiocidin, macrophages, cancer, immunotherapy, angiogenesis, cytokine, adjuvant
Abstract: The observation that many tumors exist in a microenvironment comprised of immune cells has led to the hypothesis that the immune system may play a significant role in the suppression of tumor growth. It is now clear that immune effector cells are capable of recognizing and destroying some cancer cells. However, tumors have developed numerous mechanisms by which they avoid immune recognition and death. Cancer immunotherapy attempts to harness the power of the immune system and direct it against tumor growth, while circumventing the immune-evasion strategies utilized by tumors. Many approaches are currently being investigated, including the re-infusion of autologous immune effector cells (i.e. cytotoxic T lymphocytes and macrophages) back into hosts after ex vivo expansion and activation. The therapeutic effects of specific cytokines are also being evaluated for their impact on tumor growth. Our lab has discovered a novel thrombospondin-1 (TSP-1) binding protein, termed “angiocidin”, with potent anti-tumor and anti-angiogenic capabilities. To further investigate the anti-tumor activity of angiocidin, we examined whether angiocidin could play a role in immune system modulation. We have found that the monocytic leukemia cell line THP-1, as well as freshly isolated human peripheral blood monocytes, differentiate into macrophage-like cells when treated with angiocidin. These cells underwent dramatic morphological changes and became more phagocytic. Angiocidin-treated monocytes also activated T lymphocytes in co-culture conditions. Angiocidin-treated THP-1 cells upregulated cytokine mRNA expression and secretion via NF-κB, MAPK, and PI3-K. Based on these data, we hypothesize that angiocidins ability to elicit tumor cell death may be mediated in part by its pro-inflammatory effects on immune cells in the tumor microenvironment.
Export Options
About this article
Cite this article as:
Gaurnier-Hausser A. and Tuszynski P. G., The Immunomodulatory Role of Angiocidin, a Novel Angiogenesis Inhibitor, Current Pharmaceutical Design 2009; 15 (17) . https://dx.doi.org/10.2174/138161209788453149
DOI https://dx.doi.org/10.2174/138161209788453149 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perioperative Management of Antiplatelet-Drugs in Cardiac Surgery
Current Cardiology Reviews Human ACE-2, MCP1 and micro-RNA 146 as Novel Markers for COVID- 19 Affection and Severity
Infectious Disorders - Drug Targets Diacylglycerol Kinase Inhibition and Vascular Function
Current Enzyme Inhibition Adipokines: Therapeutic Targets for Metabolic Syndrome
Current Drug Targets Stem Cell Niche in Tissue Homeostasis, Aging and Cancer
Current Medicinal Chemistry Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Revision on Renal Sympathetic Ablation in the Treatment of Resistant Hypertension
Current Hypertension Reviews Total Lipids and Fatty Acid Methyl Esters of Germinated Seeds of Mangrove Wild Legume
Current Nutrition & Food Science The Utility of Antiemetics in the Prevention and Treatment of Postoperative Nausea and Vomiting in Patients Scheduled for Laparoscopic Cholecystectomy
Current Pharmaceutical Design Use of Anti-Cancer Drugs, Mitocans, to Enhance the Immune Responses against Tumors
Current Pharmaceutical Biotechnology Cationic Liposomes for Gene Delivery: Novel Cationic Lipids and Enhancement by Proteins and Peptides
Current Medicinal Chemistry Recent Advances in Inducible Cyclooxygenase (COX-2) Inhibition.
Current Medicinal Chemistry High-Speed Screening and Quantitative SAR Analysis of Human ABC Transporter ABCG2 for Molecular Modeling of Anticancer Drugs to Circumvent Multidrug Resistance
Mini-Reviews in Medicinal Chemistry The ORL-1 Receptor System: Are There Opportunities for Antagonists in Pain Therapy?
Current Topics in Medicinal Chemistry Editorial: Challenge for the European Union: Immigrant and Refugee Health
Inflammation & Allergy - Drug Targets (Discontinued) Adenoviral Vector-Mediated Gene Transfer for Human Gene Therapy
Current Gene Therapy Contemporary Animal Models For Human Gene Therapy Applications
Current Gene Therapy Evaluation of B Lymphocyte Deficiencies
Cardiovascular & Hematological Disorders-Drug Targets Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry